# Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
Canonical URL: https://biopharmsignal.com/news/NTRB/nutriband-to-present-at-the-noble-capital-markets-emerging-growth-virtual-equity-97306bad
Ticker: NTRB
Company: Nutriband
Source: Nutriband
Published: 2025-10-08 10:30 EST
## Summary

Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that its Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual ...

## Article Body
Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that its Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Wednesday, October 8 at 15:00 Eastern Standard Time. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Scheduled 1x1 meetings with Mr. Melnik are also available for registered, qualified investor attendees.

Attendees interested in viewing the live presentation can register for this event at no cost, here: Virtual Equity Conference Registration

Qualified investors wishing to meet 1x1 with company management can reach out to Giorgia Pigato, from Noble Capital Markets, at gpigato@noblecapitalmarkets.com .

A video webcast of the presentation will be available as part of a complete catalog of presentations available on Channelchek www.channelchek.com , the investor portal created by Noble. The webcast will be archived on the company's website and on Channelchek.com for 90 days following the event.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com . Any material contained in or derived from the Company's websites or any other website is not part of this press release.

About Noble Capital Markets

Established in 1984, Noble Capital Markets is an SEC / FINRA registered full-service investment bank and advisory firm with an award-winning research team and proprietary investor distribution platform. We deliver middle market expertise to entrepreneurs, corporations, financial sponsors, and investors. Over the past 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports.

About Channelchek

Noble launched www.channelchek.com in 2018 – an investor community dedicated exclusively to public emerging growth companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 7,000 public emerging growth companies are listed on the site, and content including equity research, webcasts, and industry articles.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information :

Nutriband Inc. Phone: 407-377-6695 Email: info@nutriband.com

SOURCE: Nutriband Inc.
## Recent Company News
- 2026-05-15 11:00 EST — [Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference](https://biopharmsignal.com/news/NTRB/nutriband-inc-to-showcase-expanding-ai-wellness-product-portfolio-and-new-june-p-84b69db9) — Source: Nutriband
- 2026-04-22 11:00 EST — [Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast](https://biopharmsignal.com/news/NTRB/nutriband-ceo-gareth-sheridan-discusses-the-us-fentanyl-crisis-and-company-updat-88a89417) — Source: Nutriband
- 2026-03-30 20:05 EST — [Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch](https://biopharmsignal.com/news/NTRB/nutriband-selects-commercial-brand-name-for-its-abuse-deterrent-fentanyl-patch-08ec44c0) — Source: Nutriband
- 2026-03-18 11:00 EST — [Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica](https://biopharmsignal.com/news/NTRB/nutriband-ai-kinesiology-tapes-approved-for-distribution-and-sale-in-costa-rica-550f57ba) — Source: Nutriband
- 2026-02-17 12:28 EST — [Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica](https://biopharmsignal.com/news/NTRB/nutriband-signs-exclusive-distribution-agreement-with-innomedica-for-aversa-fent-1914d982) — Source: Nutriband
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)